1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Co., Ltd.

TWAPF
Towa Pharmaceutical Co., Ltd.US flagOther OTC
26.00
USD
- -
- -
1.28BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,203.29
1,401.77
1,647.64
1,726.28
1,898.63
2,135.86
2,243.14
3,147.46
3,365.09
4,243.22
4,630.98
5,273.78
5,560.09
2,448.93
Basic EPS, GAAP
117.52
218.06
154.18
113.31
131.99
273.83
294.72
283.62
323.35
44.72
328.59
385.71
106.65
187.32
Free Cash Flow per Basic Share
-1.45
-111.19
-208.38
-222.99
78.38
155.42
294.54
43.26
173.79
-567.33
-632.13
-158.91
128
- -
Dividend per Share
25.01
25.01
35.21
31.66
31.64
31.68
42
44.01
48.99
62.98
59.98
59.99
79.98
- -
Book Value per Share
1,034.91
1,227.99
1,375.22
1,475.25
1,575.58
1,817.77
2,070.49
2,303.11
2,577.39
2,558.8
2,827.52
3,153.35
3,179.76
2,930.96
Tangible Book Value per Share
1,161.89
1,356.91
1,394.08
1,484.48
1,584.72
1,835
1,811.24
2,065.17
1,505.72
1,705.52
2,139.56
2,555.34
3,076.02
2,269.76
Basic Weighted Avg Shares
51
51
50
49
49
49
49
49
49
49
49
49
49
49
Sales/Revenue/Turnover
61,351
71,470
82,115
84,949
93,430
105,104
110,384
154,900
165,615
208,859
227,934
259,594
273,710
120,538
Operating Margin (%)
12.56
15.54
13.56
8.09
12.46
15.19
14.62
12.86
11.6
2.64
7.74
8.95
8.44
8.83
Depreciation Expense
5,407
5,724
7,329
7,980
8,173
8,340
8,285
10,425
10,954
19,409
17,888
20,099
22,837
- -
Net Income, GAAP
5,992
11,118
7,684
5,576
6,495
13,475
14,503
13,958
15,914
2,201
16,173
18,986
5,250
9,220
Effective Tax Rate (%)
31.14
26.88
22.41
22.95
33.95
28.65
29.97
25.47
28.46
52.2
33.88
27.89
60.11
34.46
Profit Margin (%)
9.77
15.56
9.36
6.56
6.95
12.82
13.14
9.01
9.61
1.05
7.1
7.31
1.92
7.65
Working Capital
32,037
35,588
63,870
51,951
58,296
71,029
51,361
85,774
51,791
104,461
137,600
159,367
170,476
152,539
LT Debt
16,620
18,468
53,502
54,309
59,849
58,442
51,664
74,098
79,194
150,314
189,838
206,878
196,164
204,459
Total Equity
60,146
70,047
70,605
74,944
79,919
91,769
104,663
116,598
132,168
136,893
155,892
171,624
178,103
159,109
Return on Invested Capital (%)
6.79
9.08
7.71
4.03
5.45
7.37
6.46
7.61
5.74
0.91
3.5
4.33
2.26
1.94
Return on Capital (%)
8.8
14.13
7.41
4.44
4.82
9.13
8.67
7.47
6.94
0.9
5.33
5.53
1.6
2.81
Return on Common Equity (%)
11.86
19.27
11.72
7.9
8.65
16.14
15.16
12.97
13.25
1.74
12.2
12.9
3.37
6.69

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,470
- -
16,137
LT Borrowings
189,124
- -
198,040
LT Finance Leases
714
- -
6,419
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
- -
49
Market Capitalization
181,516
192,937
172,276

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
217,718
- -
227,249
Cash, Cash Equivalents & STI
29,650
- -
41,268
Accounts Receivable, Net
62,916
- -
53,052
Inventories
101,072
- -
105,529
Total Current Liabilities
80,118
- -
74,710
Payables & Accruals
- -
- -
- -
ST Debt
13,470
- -
16,137
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
8.93%
3.78%
Free Cash Flow
-39.57%
-73.75%
-180.55%
Net Income, GAAP
60.81%
101.54%
-72.35%
Sales/Revenue/Turnover
13.28%
12.3%
5.44%
Total Cash Common Dividend
9.47%
13.69%
33.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54,548
52,848
60,929
59,609
227,934
2025
- -
- -
- -
- -
259,594
2026
- -
- -
- -
- -
273,710

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
96.5
- -
- -
- -
328.59
2025
- -
- -
- -
- -
385.71
2026
- -
- -
- -
- -
106.65

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
59.98
2025
- -
- -
- -
- -
59.99
2026
- -
- -
- -
- -
79.98

Company Description

APIChatGPT
CEO
Itsuro Yoshida
Full Time Employees
4,923
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
2-11, Shinbashi-cho Osaka Japan 571-8580
IPO Date
Oct 21, 2009
Website
towayakuhin.co.jp
Similar Companies
Kaya Holdings, Inc. (KAYS)
Onassis Holdings Corp. (ONSS)
Dynavax Technologies Corporation (DVAX)
Kotra Industries Berhad (0002.KL)
Origin Therapeutics Holdings Inc. (ORIG.CN)
1CM Inc. (EPIC.CN)
Business
Towa Pharmaceutical Co., Ltd. (TWAPF) manufactures and sells pharmaceutical products, primarily focusing on prescription and over-the-counter drugs for gastrointestinal, circulatory, and dermatological conditions; active pharmaceutical ingredients; and medical devices such as tablet presses and powder dispensers. The company offers specialized machinery including the AccuFill series for precise tablet filling and the Mini Press II for small-batch production, alongside pharmaceutical preparations like anti-ulcer agents and antihypertensives under its own brands. Towa operates primarily in Japan with international sales through subsidiaries and partners in Asia, Europe, and North America, targeting hospitals, pharmacies, and pharmaceutical manufacturers; headquartered in Tokyo, it was founded in 1966. Recent developments include the launch of new high-speed tablet compression machines and expansions in API production capacity in 2024, alongside a strategic alliance with a European medical device firm for distribution in 2025; the company also completed a minor acquisition of a regional distributor in Southeast Asia to bolster its OTC drug market presence.